Genetically‐Engineered Pigs as a Source of Blood Products
Xenotransplantation · 2026-01 · 33 (1)
DOI: 10.1111/xen.70114 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Xenotransplantation, online erschienen am 24.02.2026. Verfasst von Aaron C K Lucander und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, USA. Hauptthemen laut MEDLINE: Transplantation, Heterologous, Animals, Genetically Modified, Blood Transfusion. Die Arbeit nennt 64 Literaturangaben. Gefördert von: NIH NIAID U19, US DHHS, American Society of Nephrology.
Abstract (Originalsprache)
Whole blood and its constituents are primary treatments for numerous human patients with a vast array of clinical conditions. Each year, these include >10 million blood transfusions performed in the USA and approximately 16 million patients globally that receive plasma‐derived medicinal products costing $30 billion. As the clinical indications and demand for blood products continue to grow, there is a critical impetus for establishing sources that are more reliable, cost‐effective, and efficacious than the current system that is largely built around samples derived from human donors. In particular, genetically‐engineered pigs that have been developed for solid organ xenotransplantation could also serve as a source of blood products, representing a potential source for fulfilling global clinical needs. Here we provide an overview of the blood product economy and assess the feasibility of genetically‐engineered pigs as a source of clinical‐grade blood products for use in human recipients. Although the potential need for these products is immense, we draw attention to the special requirement for them in patients with pig organ grafts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
- Center For Transplantation Sciences, Department of Surgery, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, USA.
Förderung
- NIH NIAID U19
- US DHHS
- American Society of Nephrology
Zitieren
APA
Lucander, A. C. K., & Cooper, D. K. C. (2026). Genetically‐Engineered Pigs as a Source of Blood Products. Xenotransplantation, 33(1). https://doi.org/10.1111/xen.70114
Vancouver
Lucander ACK, Cooper DKC. Genetically‐Engineered Pigs as a Source of Blood Products. Xenotransplantation. 2026;33(1). doi:10.1111/xen.70114
BibTeX
@article{Lucander2026,
author = {Lucander, Aaron C K and Cooper, David K C},
title = {Genetically‐Engineered Pigs as a Source of Blood Products},
journal = {Xenotransplantation},
year = {2026},
volume = {33},
number = {1},
doi = {10.1111/xen.70114}
}
EUVIMED